Background: The incidence of anal cancer has increased over at least the past decade, with estimates of a continued increase in the coming years. Women are more commonly affected than men in the general population; separate high-risk populations have also been identified. While the pathophysiology of anal cancer is thought to be similar to its cervical counterpart, well-defined and standardized screening guidelines have not been established as is seen in cervical cancer prevention. Nonetheless, multiple screening modalities have been examined and are components of proposed institutional and societal screening programs. Summary: Anal cytology is one modality that is a mainstay of many suggested screening guidelines. Interpretation and reporting follow current criteria for cervical/vaginal cytology per the Bethesda System, with site-specific alterations and changes in adequacy criteria to better accommodate some of the confounding factors encountered in anal cytology. While there are some limitations, such as a tendency to underestimate the degree of dysplasia and variable interobserver concordance rates, anal cytology, especially liquid-based preparations, overall performs well in detecting anal abnormalities and acts as an adequate screening tool. Importantly, most anal squamous dysplasias and cancers are also associated with human papillomavirus (HPV) infection, raising the possibility of HPV testing or genotyping as a component of screening and/or follow-up. Studies have also shown the efficacy of HPV vaccination in preventing anal lesions. Digital anorectal exam as well as anoscopy, particularly high-resolution anoscopy, are also often components of screening and follow-up. Management guidelines such as those put forth by the American Society for Colposcopy and Cervical Pathology (ASCCP) for cervical cancer are also not established for anal cancer. However, studies such as the Anal Cancer HSIL Outcomes Research (ANCHOR) trial have made significant strides in demonstrating successes in follow-up and treatment of anal lesions, findings that are crucial for establishing prevention and management guidelines going forward.

1.
Surveillance Research Program. SEER cancer stat facts: anal cancer. Bethesda, MD: National Cancer Institute; 2019.
2.
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33.
3.
Wohlmuth C, Ghorab Z, Shier M, Tinmouth J, Salit IE, Covens A, et al. Cytology-based screening for anal intraepithelial neoplasia in women with a history of cervical intraepithelial neoplasia or cancer. Cancer Cytopathol. 2021;129(2):140–7.
4.
Cimic A, Wilkin TJ, Heymann JJ, Alperstein S, Ellsworth G, Siddiqui MT. Importance of anal cytology and screening for anal dysplasia in individuals living with HIV with an emphasis on women. Cancer Cytopathol. 2019;127(6):407–13.
5.
Albuquerque A. Cytology in anal cancer screening: practical review for clinicians. Acta Cytol. 2020;64(4):281–7.
6.
Albuquerque A, Medeiros R. New insights into the role of human papillomavirus in anal cancer and anal wart development. Acta Cytol. 2019;63(2):118–23.
7.
Hopp AM, Pant M, Sniedze S, Parsons LN, Hunt B, Giorgadze T. Correlation of anal cytology with follow-up histology and human papillomavirus genotyping: a 10-year experience from an academic medical center. Ann Diagn Pathol. 2021;50:151670.
8.
Schiffman M, Wentzensen N, Wacholder S, Kinney W, Gage JC, Castle PE. Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst. 2011;103(5):368–83.
9.
Leeds IL, Fang SH. Anal cancer and intraepithelial neoplasia screening: a review. World J Gastrointest Surg. 2016;8(1):41–51.
10.
Roberts JM, Jin F, Thurloe JK, Ekman D, Adams MK, McDonald RL, et al. The value of a transformation zone component in anal cytology to detect HSIL. Cancer Cytopathol. 2016;124(8):596–601.
11.
Albuquerque A, Rios E, Schmitt F. Recommendations favoring anal cytology as a method for anal cancer screening: a systematic review. Cancers (Basel). 2019;11(12):1942.
12.
Revollo B, Videla S, Llibre JM, Paredes R, Pinol M, Garcia-Cuyas F, et al. Routine screening of anal cytology in persons with human immunodeficiency virus and the impact on invasive anal cancer: a prospective cohort study. Clin Infect Dis. 2020;71(2):390–9.
13.
Morency EG, Harbert T, Fatima N, Samolcyzk J, Maniar KP, Nayar R. Anal cytology: institutional statistics, correlation with histology, and development of multidisciplinary screening program with review of the current literature. Arch Pathol Lab Med. 2019;143(1):23–9.
14.
Berry JM, Palefsky JM, Jay N, Cheng SC, Darragh TM, Chin-Hong PV. Performance characteristics of anal cytology and human papillomavirus testing in patients with high-resolution anoscopy-guided biopsy of high-grade anal intraepithelial neoplasia. Dis Colon Rectum. 2009;52(2):239–47.
15.
Brasseur B, Subillaga O, Vrees M, Klipfel A, Roth L, Schechter S. Can anal cytology Be a tool in following patients treated for squamous cell carcinoma of the anus? Am Surg. 2022;88(7):1621–5.
16.
Hirsch BE, McGowan JP, Fine SM, Vail R, Merrick ST, Radix A, et al. Screening for anal dysplasia and cancer in adults with HIV [Internet]. 2022.
17.
Pisano L, Tiradritti L, Lorenzoni E, Zuccati G, Foxi P, Butera D, et al. Liquid-based anal cytology as a screening tool for prevention of anal cancer in at-risk populations: a single-center retrospective analysis on 111 patients. Journal of Coloproctology. 2021;41(04):419–24.
18.
Pisano L, Grandi V, Tiradritti L, Zuccati G, Caminati F, Giani I, et al. New screening strategy combining anal Papanicolaou and human papillomavirus tests for human papillomavirus-related anal cancer: a prospective, single-center study. Sex Transm Dis. 2022;49(9):622–7.
19.
Bean SM, Chhieng DC, Roberson J, Raper JL, Broker TR, Hoesley CJ, et al. Anal-rectal cytology: correlation with human papillomavirus status and biopsy diagnoses in a population of HIV-positive patients. J Low Genit Tract Dis. 2010;14(2):90–6.
20.
Gudur A, Shanmuganandamurthy D, Szep Z, Poggio JL. An update on the current role of high resolution anoscopy in patients with anal dysplasia. Anticancer Res. 2019;39(1):17–23.
21.
Nayar R, Wilbur D. The Bethesda system for reporting cervical cytology: definitions, criteria, and explanatory notes. 3rd ed. New York: Springer; 2015.
22.
Bean SM, Chhieng DC. Anal-rectal cytology: a review. Diagn Cytopathol. 2010;38(7):538–46.
23.
Chin-Hong PV, Berry JM, Cheng SC, Catania JA, Da Costa M, Darragh TM, et al. Comparison of patient- and clinician-collected anal cytology samples to screen for human papillomavirus-associated anal intraepithelial neoplasia in men who have sex with men. Ann Intern Med. 2008;149(5):300–6.
24.
Cranston RD, Darragh TM, Holly EA, Jay N, Berry JM, Da Costa M, et al. Self-collected versus clinician-collected anal cytology specimens to diagnose anal intraepithelial neoplasia in HIV-positive men. J Acquir Immune Defic Syndr. 2004;36(4):915–20.
25.
Sherman ME, Friedman HB, Busseniers AE, Kelly WF, Carner TC, Saah AJ. Cytologic diagnosis of anal intraepithelial neoplasia using smears and cytyc thin-preps. Mod Pathol. 1995;8(3):270–4.
26.
Darragh TM, Jay N, Tupkelewicz BA, Hogeboom CJ, Holly EA, Palefsky JM. Comparison of conventional cytologic smears and ThinPrep preparations from the anal canal. Acta Cytol. 1997;41(4):1167–70.
27.
Maia LB, Marinho LC, Wanderley Paes Barbosa T, Batalha Filho ES, Ribeiro Velasco LF, Garcia Costa PG, et al. A comparative study between conventional and liquid-based cytology in screening for anal intraepithelial lesions in HIV-positive patients. Diagn Cytopathol. 2014;42(10):840–5.
28.
DPDx-Laboratory. Identification of parasites of public health concern. Centers for disease control and prevention. 2019 [Updated November 20, 2019]. https://www.cdc.gov/dpdx/az.html (accessed August 25, 2022).
29.
Schuetz AN, Pritt BS, Schreiner AM. Iodamoeba butschlii in an anal pap test confirmed by iodine stain. Diagn Cytopathol. 2014;42(9):775–7.
30.
Darragh TM, Tokugawa D, Castle PE, Follansbee S, Borgonovo S, LaMere BJ, et al. Interrater agreement of anal cytology. Cancer Cytopathol. 2013;121(2):72–8.
31.
Darragh TM, Winkler B, Souers RJ, Laucirica R, Zhao C, Moriarty AT, et al. Room for improvement: initial experience with anal cytology: observations from the college of american pathologists interlaboratory comparison program in nongynecologic cytology. Arch Pathol Lab Med. 2013;137(11):1550–4.
32.
Albuquerque A, Sheaff M, Stirrup O, Cappello C, Bowring J, Cuming T, et al. Performance of anal cytology compared with high-resolution anoscopy and histology in women with lower anogenital tract neoplasia. Clin Infect Dis. 2018;67(8):1262–8.
33.
Pernot S, Boucheron P, Péré H, Lucas ML, Veyer D, Fathallah N, et al. Comparison of anal cancer screening strategies including standard anoscopy, anal cytology, and HPV genotyping in HIV-positive men who have sex with men. Br J Cancer. 2018;119(3):381–6.
34.
Alemany L, Saunier M, Alvarado-Cabrero I, Quiros B, Salmeron J, Shin HR, et al. Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide. Int J Cancer. 2015;136(1):98–107.
35.
Giuliano AR, Palefsky JM, Goldstone S, Moreira ED Jr, Penny ME, Aranda C, et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med. 2011;364(5):401–11.
36.
Palefsky JM, Giuliano AR, Goldstone S, Moreira ED Jr, Aranda C, Jessen H, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med. 2011;365(17):1576–85.
37.
Swedish KA, Factor SH, Goldstone SE. Prevention of recurrent high-grade anal neoplasia with quadrivalent human papillomavirus vaccination of men who have sex with men: a nonconcurrent cohort study. Clin Infect Dis. 2012;54(7):891–8.
38.
Palefsky JM, Lensing SY, Belzer M, Lee J, Gaur AH, Mayer K, et al. High prevalence of anal high-grade squamous intraepithelial lesions, and prevention through human papillomavirus vaccination, in young men who have sex with men living with human immunodeficiency virus. Clin Infect Dis. 2021;73(8):1388–96.
39.
Centers for disease control and prevention. Vaccines and preventable diseases. Administering HPV vaccine. 2021 [Updated November 16, 2021]. https://www.cdc.gov/vaccines/vpd/hpv/hcp/administration.html (accessed August 25, 2022).
40.
Markowitz LE, Dunne EF, Saraiya M, Chesson HW, Curtis CR, Gee J, et al. Human papillomavirus vaccination: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep. 2014;63(RR-05):1–30.
41.
The Kirby Institute. Study of the prevention of anal cancer (SPANC) trial. Kensington, Australia: University of New South Wales; 2022.
42.
Palefsky JM, Lee JY, Jay N, Goldstone SE, Darragh TM, Dunlevy HA, et al. Treatment of anal high-grade squamous intraepithelial lesions to prevent anal cancer. N Engl J Med. 2022;386(24):2273–82.
43.
Perkins RB, Guido RS, Castle PE, Chelmow D, Einstein MH, Garcia F, et al. 2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis. 2020;24(2):102–31.
44.
Nayar R, Chhieng DC, Crothers B, Darragh TM, Davey DD, Eisenhut C, et al. Moving forward-the 2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors and beyond: implications and suggestions for laboratories. J Am Soc Cytopathol. 2020;9(4):291–303.
45.
European Centre for Disease Prevention and Control. Guidance on HPV vaccination in EU countries: focus on boys, people living with HIV and 9-valent HPV vaccine introduction. Stockholm; 2020. Vol(1–54).
46.
Arbyn M, Gultekin M, Morice P, Nieminen P, Cruickshank M, Poortmans P, et al. The European response to the WHO call to eliminate cervical cancer as a public health problem. Int J Cancer. 2021;148(2):277–84.
47.
Smith MA, Liu B, McIntyre P, Menzies R, Dey A, Canfell K. Fall in genital warts diagnoses in the general and indigenous Australian population following implementation of a national human papillomavirus vaccination program: analysis of routinely collected national hospital data. J Infect Dis. 2015;211(1):91–9.
48.
Machalek DA, Garland SM, Brotherton JML, Bateson D, McNamee K, Stewart M, et al. Very low prevalence of vaccine human papillomavirus types among 18-to 35-year old Australian women 9 years following implementation of vaccination. J Infect Dis. 2018;217(10):1590–600.
49.
Australian Institute of Health and Welfare. Cervical screening in Australia 2014–2015. Cancer series no. 105. Cat. No. CAN 104. Canberra: AIHW; 2017.
50.
Department of Health and Human Services, Centers for Medicare and Medicaid Services. Clinical laboratory improvement amendments of 1988; final rule. Fed Register. 2003 Jan 24:7169.
You do not currently have access to this content.